Wednesday, July 30, 2014 9:48:55 AM
"The company's new CEO, Kenneth Manzo, is a licensed Pharmacist with 25 years of experience in the pharmaceutical industry. With his vast knowledge of prescription drugs, over the counter medications, and natural remedies, he founded Manzo Pharmaceuticals for the purpose of testing and development of his patented processes as well as the creation of many other unique remedies. Manzo wants shareholders to know that he plans to be as transparent as possible while protecting the intellectual property the company now owns. He also wants shareholders to know he will go to great lengths to avoid unnecessary dilution, and despite a sizable number of shares outstanding, he vows not to do a reverse split or other damaging corporate action."
This is an assurance given by the CEO to say there wont be any RS in the near future.
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM